Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease
Myrthe J. van Dijk(Utrecht University), Richard van Wijk(Utrecht University), Marije Bartels(University Medical Center Utrecht), Titine Ruiter(Utrecht University), Marjon H. Cnossen(Erasmus MC), Erfan Nur(Sanquin), Minke A.E. Rab(Utrecht University), Wouter W. van Solinge(Utrecht University), Roger E. G. Schutgens(University Medical Center Utrecht), Cleo Derichs(Utrecht University), Anita W. Rijneveld(Erasmus MC Cancer Institute), Bart J. Biemond(Amsterdam University Medical Centers), Judith Jans(University Medical Center Utrecht), Brigitte A. van Oirschot(Utrecht University), Eduard J. van Beers(Utrecht University), Jennifer Bos(Utrecht University), Sigrid van der Veen(Utrecht University)
Cited by 14
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309
Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
|Blood|2017|300
Clinical severity of haemophilia A: does the classification of the 1950s still stand?
|Haemophilia|2011|244
COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
|The Lancet Haematology|2021|237